Trevi Therapeutics Inc (TRVI) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $11.52
• Market Cap: $1.46B
• EPS: $-0.37
• 52-Week High: $14.39
• 52-Week Low: $4.17

Market Sentiment

Trevi Therapeutics Inc currently has a Bullish sentiment score of 0.29.

About Trevi Therapeutics Inc

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing innovative therapies for patients with serious neurology-mediated conditions. The firm's lead product candidate, Haduvio, targets significant unmet medical needs and is currently undergoing clinical trials. With a strong focus on advancing its pipeline and leveraging its expertise in drug development, Trevi Therapeutics is well-positioned to make a meaningful impact ...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Trevi Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does TRVI pay dividends?

Trevi Therapeutics Inc (TRVI) does not currently pay a regular dividend.

What is TRVI's market cap?

Trevi Therapeutics Inc (TRVI) has a market capitalization of $1.46B with a current stock price of $11.52.